Status:

COMPLETED

Fasted Bioequivalence Study of Primidone Tablets and Mysoline Tablets

Lead Sponsor:

Mutual Pharmaceutical Company, Inc.

Conditions:

Therapeutic Equivalency

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline®(primidone tablets) in adult sub...

Detailed Description

The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline® (primidone tablets) in adult su...

Eligibility Criteria

Inclusion

  • male or female
  • at least 18 years of age
  • weight must be 15% of ideal weight for height and frame
  • subjects must be in good health and physical condition as determined by medical history
  • subjects must read and sign consent form

Exclusion

  • history of treatment for alcoholism, substance abuse, or drug abuse within the last 24 months
  • history of malignancy, stroke, diabetes, cardiac, renal or liver disease
  • history of gastroesophageal reflux disease (GERD), malabsorption syndrome, colon cancer, chronic colitis, including Crohn's disease
  • history of porphyria, hyperkinesia, respiratory diseases (eg. asthma, emphysema, difficulty breathing, pulmonary obstruction)
  • females who pregnant or lactating
  • history of hypersensitivity to primidone, barbiturates, and anticonvulsants
  • sitting systolic blood pressure below 90mm Hg, or diastolic pressure below 50mm Hg (conditions upon screening which might contraindicate or require that caution be used in the administration of primidone)
  • heart rate less than 50 beats per minute after a 5 minute rest
  • treatment with any other investigational drug during the four weeks prior to initial dosing
  • subjects who have donated blood within four weeks prior to the initial dosing
  • subjects who smoke or use tobacco products or nicotine products. Three months abstinence is required.

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2004

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT00685165

Start Date

May 1 2004

End Date

June 1 2004

Last Update

January 20 2010

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.